First-in-human RCT of 104 CMV-seronegative adults: CMV-gB vaccine with SPA09 adjuvant (low or high dose) gave higher neutralising antibody and cellular responses than with AF03; safety was acceptable, but reactogenicity was higher with SPA09HD.
RCTn = 104
Pichon et al. Safety and immunogenicity of a cytomegalovirus (CMV) recombinant glycoprotein B (gB) vaccine in combination with polyacrylate or an emulsion-based adjuvants